Fragility of epidermis and its consequence in dermatology

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue SUPPL. 4, 2014, Pages 1-18

  Stalder, J F ^a   Tennstedt, D ^b   Deleuran, M ^c   Fabbrocini, G ^d   De Lucas, R ^e   Haftek, M ^f   Taieb, C ^g   Coustou, D ^h   Mandeau, A ⁱ   Fabre, B ⁱ   Hernandez Pigeon, H ^g   Aries, M F ^g   Galliano, M F ^g   Duplan, H ^g   Castex Rizzi, N ^g   Bessou Touya, S ^g   Mengeaud, V ^g   Rouvrais, C ^g   Schmitt, A M ^g   Bottino, R ^g   Cottin, K ^g   Saint Aroman, M ^g   more..

^a NANTES UNIVERSITY HOSPITAL   (France)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSITÉ LYON 1   (France)

^g Centre d'Immunologie Pierre Fabre   (France)

^h Dermatologists   (France)

ⁱ INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYANOCOBALAMIN; DERMATOLOGICAL AGENT; FILAGGRIN; INTRINSIC FACTOR; ISOTRETINOIN; PLANT EXTRACT; RETINOID; RHEALBA OAT; RHEALBA OAT PLANTLET EXTRACT; UNCLASSIFIED DRUG; EMOLLIENT AGENT;

ACNE; ADAPTIVE IMMUNITY; ARTICLE; ATOPIC DERMATITIS; CHILDHOOD DISEASE; CIRCUMSTANTIAL FRAGILE SKIN; CLINICAL FEATURE; CLINICAL PRACTICE; CONTACT DERMATITIS; DERMATOLOGY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG EFFECT; ENVIRONMENTAL FACTOR; EPIDERMIS; ESTHETIC SURGERY; HISTOPATHOLOGY; HUMAN; IATROGENIC DISEASE; IATROGENIC FRAGILE SKIN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PATHOLOGICAL FRAGILE SKIN; PATHOPHYSIOLOGY; PERMEABILITY BARRIER; PHYSIOLOGICAL FRAGILE SKIN; PLANTLET; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PSORIASIS; ROSACEA; SENSITIVE SKIN SYNDROME; SKIN DISEASE; SKIN FRAGILITY; SKIN FUNCTION; SKIN PROTECTION; SKIN REDNESS; SKIN SENSITIVITY; SKIN WATER LOSS; STRESS; ACNE VULGARIS; DERMATITIS, ATOPIC; DERMATITIS, CONTACT; DRUG EFFECTS; ECZEMA; EPIDERMOLYSIS BULLOSA; IMMUNOLOGY; OAT; PATHOLOGY; PHYSIOLOGY; PHYTOTHERAPY; SKIN DISEASES;

ACNE VULGARIS; AVENA SATIVA; DERMATITIS, ATOPIC; DERMATITIS, CONTACT; ECZEMA; EMOLLIENTS; EPIDERMIS; EPIDERMOLYSIS BULLOSA; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PSORIASIS; RETINOIDS; SKIN DISEASES;

EID: 84902802618     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12509     Document Type: Article

References (73)

1. Whittock NV, Haftek M, Angoulvant N, et al,. Genomic amplification of the human plakophilin 1 gene (PKP1) and detection of a new mutation in ectodermal dysplasia/skin fragility syndrome. J Invest Dermatol 2000; 115: 368-374.
2. Whittock NV, Wan H, Morley SM, et al,. Compound heterozygosity for nhon-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol 2002; 118: 232-238. (Pubitemid 34158475)
3. Haftek M, Simon M, Kanitakis J, et al,. Expression of corneodesmosin in the granular layer and stratum corneum of normal and diseased epidermis. Br J Dermatol 1997; 137: 864-873. (Pubitemid 28011125)
4. Simon M, Jonca N, Guerrin M, et al,. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 2001; 276: 20292-20299. Erratum in: J Biol Chem 2001; 276(50):47742-3.
5. Oji V, Eckl KM, Aufenvenne K, et al,. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010; 87: 274-281. doi: 10.1016/j.ajhg.2010.07.005.
6. Blaydon DC, Nitoiu D, Eckl KM, et al,. Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion. Am J Hum Genet 2011; 89: 564-571. doi: 10.1016/j.ajhg.2011.09.001.
7. Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H,. Keratin gene mutations in disorders of human skin and its appendages. Arch Biochem Biophys 2011; 508: 123-137. doi: 10.1016/j.abb.2010.12.019.
8. Carulli S, Contin R, De Rosa L, Pellegrini G, De Luca M,. The long and winding road that leads to a cure for epidermolysis bullosa. Regen Med 2013; 8: 467-481. doi: 10.2217/rme.13.33.
9. Kiritsi D, Cosgarea I, Franzke CW, et al,. Acral peeling skin syndrome with TGM5 gene mutations may resemble epidermolysis bullosa simplex in young individuals. J Invest Dermatol 2010; 130: 1741-1746. doi: 10.1038/jid.2010.23.
10. 2+ pump dysfunction. Biofactors 2011; 37: 150-158. doi: 10.1002/biof.141.
11. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ,. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 1998; 77â: 31-37.
12. Miyake N, Kosho T, Mizumoto S, et al,. Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome. Hum Mutat 2010; 31: 966-974.
13. Nikolovska K, Renke JK, Jungmann O, et al,. A decorin-deficient matrix affects skin chondroitin/dermatan sulfate levels and keratinocyte function. Matrix Biol 2014. doi: 10.1016/j.matbio.2014.01.003 [Epub ahead of print].
14. McAleer MA, Irvine AD,. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol 2013; 131: 280-291. doi: 10.1016/j.jaci.2012.12.668.
15. Fortugno P, Furio L, Teson M, et al,. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Hum Mol Genet 2012; 21: 4187-4200. doi: 10.1093/hmg/dds243.
16. Imokawa G,. Lipid abnormalities in atopic dermatitis. J Am Acad Dermatol 2001; 45 (Suppl. 1): S29-S32. (Pubitemid 32661822)
17. van Smeden J, Janssens M, Kaye EC, et al,. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol 2014; 23: 45-52. doi: 10.1111/exd.12293.
18. Elias PM, Brown BE, Ziboh VA,. The permeability barrier in essential fatty acid deficiency: evidence for a direct role for linoleic acid in barrier function. J Invest Dermatol 1980; 74: 230-233. (Pubitemid 10039869)
19. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP,. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 2007; 104: 5079-5084. (Pubitemid 47186179)
20. Hanakawa Y, Stanley JR,. Mechanisms of blister formation by staphylococcal toxins. J Biochem 2004; 136: 747-750. (Pubitemid 40364163)
21. Schwartz RA, McDonough PH, Lee BW,. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69: 173.e1-13; quiz 185-6. doi: 10.1016/j.jaad.2013.05.003.
22. Al-Himdani S, Ud-Din S, Gilmore S, Bayat A,. Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment. Br J Dermatol 2014; 170: 527-547.
23. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H,. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 1998; 141: 1277-1286. (Pubitemid 28265620)
24. Leblanc K, Baranoski S, Holloway S, Langemo D, Regan M,. A descriptive cross-sectional international study to explore current practices in the assessment, prevention and treatment of skin tears. Int Wound J 2014. Jan 21. doi: 10.1111/iwj.12203 [Epub ahead of print].
25. Haftek M, Coutanceau C, Taïeb C,. Epidemiology of "fragile skin": results from a survey of different skin types. Clin Cosmet Investig Dermatol 2013; 6: 289-294. doi: 10.2147/CCID.S55223.
26. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A,. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PLoS ONE 2012; 7: e39803.
27. Beattie PE, Lewis-Jones MS,. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006; 155: 145-151. (Pubitemid 43876407)
28. Gil KM, Keefe FJ, Sampson HA, McCaskill CC, Rodin J, Crisson JE,. The relation of stress and family environment to atopic dermatitis symptoms in children. J Psychosom Res 1987; 31: 673-684. (Pubitemid 17167530)
29. Schmitt J, Apfelbacher C, Heinrich J, Weidinger S, Romanos M,. [ Association of atopic eczema and attention-deficit/hyperactivity disorder-meta-analysis of epidemiologic studies.] Z Kinder Jugendpsychiatr Psychother 2013; 41: 35-42; quiz 42-4.
30. Moret L, Anthoine E, Aubert-Wastiaux H, et al,. TOPICOP(c): a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS ONE 2013; 8: e76493.
31. Staab D, Diepgen TL, Fartasch M, et al,. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-938.
32. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
33. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M,. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J Invest Dermatol 2011; 131: 150-157.
34. Grimalt R, Mengeaud V, Cambazard F,; Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214: 61-67. (Pubitemid 46033003)
35. Hanifin J, Gupta AK, Rajagopalan R,. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528-537. (Pubitemid 35015290)
36. Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al,. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-1356.
37. Wollenberg A, Reitamo S, Atzori F, et al,. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742-750.
38. Bhate K, Williams HC,. Epidemiology of acne vulgaris. Br J Dermatol 2013; 168: 474-485. doi: 10.1111/bjd.12149.
39. Beylot C, Auffret N, Poli F, et al,. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol 2014; 28: 271-278.
40. Del Rosso JQ,. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. J Drugs Dermatol 2013; 12: 626-631.
41. Thiboutot D, Del Rosso JQ,. Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier? J Clin Aesthet Dermatol 2013; 6: 18-24.
42. Yamamoto A, Takenouchi K, Ito M,. Impaired water barrier function in acne vulgaris. Arch Dermatol Res 1995; 287: 214-218.
43. Levin J, Friedlander SF, Del Rosso JQ,. Atopic dermatitis and the stratum corneum: part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin. J Clin Aesthet Dermatol 2013; 6: 49-54.
44. Kurokawa I, Mayer-da-Silva A, Gollnick H, Orfanos CE,. Monoclonal antibody labeling for cytokeratins and filaggrin in the human pilosebaceous unit of normal, seborrhoeic and acne skin. J Invest Dermatol 1988; 91: 566-571. (Pubitemid 19016557)
45. Draelos ZD, Ertel KD, Berge CA,. Facilitating facial retinization through barrier improvement. Cutis 2006; 78: 275-281. (Pubitemid 44720416)
46. Weber SU, Thiele JJ, Han N, et al,. Topical alpha-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. Free Radic Biol Med 2003; 34: 170-176. (Pubitemid 36084321)
47. Herane MI, Fuenzalida H, Zegpi E, et al,. Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase-a double-blind, randomized, placebo-controlled study. J Cosmet Dermatol 2009; 8: 181-185.
48. Stücker M, Hoffman M, Altmeyer P,. Instrumental evaluation of retinoid-induced skin irritation. Skin Res Technol 2002; 8: 133-140. (Pubitemid 34692973)
49. Tagami H, Tadaki T, Obata M, Koyama J,. Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in guinea-pigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol 1992; 127: 470-475.
50. Elias PM,. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 1986; 15 (4 Pt 2): 797-809. (Pubitemid 17170784)
51. Tanghetti EA,. Cleanser and moisturizer use with tazarotene 0.1% cream for acne vulgaris. Poster presented at Fall Clinical Dermatology. Las Vegas, NV, 2010.
52. Guerrero D,. Dermo-cosmetic approach to acne by the dermatologist. Ann Dermatol Venereol 2010; 137 (Suppl. 2): S76-S80. doi: 10.1016/S0151-9638(10) 70032-6.
53. ® inhibits A23187-stimulated arachidonic acid mobilization, eicosanoid release, and cPLA2 expression in human keratinocytes: potential in cutaneous inflammatory disorders. Biol Pharm Bull 2005; 28: 601-606. (Pubitemid 40879922)
54. Farage MA,. Does sensitive skin differ between men and women? Cutan Ocul Toxicol 2010; 29: 153-163.
55. Ständer S, Scheneider SW, Weishaupt C, Luger TA, Misery L,. Putative neuronal mechanisms of sensitive skin. Exp Dermatol 2009; 18: 417-423.
56. Misery L, Boussetta S, Nocera T, Pérez-Cullel N, Taieb C,. Sensitive skin in Europe. J Eur Acad Dermatol Venereol 2009; 23: 376-381.
57. Conrado LA, Hounie AG, Diniz JB, et al,. Body dysmorphic disorder among dermatologic patients: prevalence and clinical features. J Am Acad Dermatol 2010; 63: 235-243.
58. Di Nardo A, Sugino K, Wertz P, Ademola J, Maibach HI,. Sodiumlauryl sulfate (SLS) induced irritant contact dermatitis: a correlation study between ceramides and in vivo parameters of irritation. Contact Dermatitis 1996; 35: 86-91. (Pubitemid 26385640)
59. Kueper T, Krohn M, Haustedt LO, Schmaus G, Vielhaber G,. Inhibition of TRPV1 for the treatment of sensitive skin. Exp Dermatol 2010; 19: 980-986.
60. Escalas-Taberner J, Segura Rodríguez R, Guerra Tapia A,. " La piel sensible." Más dermatología 2011; 13: 4-13.
61. Saint-Martory C, Roguedas-Contios AM, Sibaud V, Degouy A, Schmitt AM, Misery L,. Sensitive skin is not limited to the face. Br J Dermatol 2008; 158: 130-133. (Pubitemid 350221911)
62. Frosch PJ, Kligman AM,. A method of a praising the stinging capacity of topically applied substances. J Soc Cosmet Chem 1977; 28: 197-209. (Pubitemid 8138161)
63. Thiers H,. Peau sensible. In, Thiers H, ed. Les Cosmétiques, 2nd edn. Masson, Paris, 1986: 266-268.
64. Misery L,. Peaux réactives: mythe ou réalité? Réalités Thérapeutiques en Dermato- Vénéréologie, N°157, Cahier 1, May 2006.
65. Misery L, Martin N, Myon E, Nocera T, Taieb C,. Sensitive skin: epidemiology and seasonal variations. J Invest Dermatol 2005; 125: A24.
66. Misery L, Myon E, Martin N, Verriere F, Nocera T, Taieb C,. Peaux sensibles en France: approche épidémiologique. Ann Dermatol Venereol 2005; 132: 425-429. (Pubitemid 40774855)
67. Willis CM, Shaw S, de Lacharrière O, et al,. Sensitive skin: an epidemiological study. Br J Dermatol 2001; 145: 258-263. (Pubitemid 32955351)
68. Robinson MK,. Population differences in acute skin irritation response. Contact Dermatits 2002; 46: 86-93.
69. Primavera G, Berardesca E,. Sensitive skin: mechanisms and diagnosis. Int J Cosmet Sci 2005; 27: 1-10. (Pubitemid 40313409)
70. Pons-Guiraud A,. Sensitive skin: a complex and multifactorial syndrome. J Cosmet Dermatol 2004; 3: 145-148.
71. Misery L,. Les nerfs à fleur de peau. Int J Cosmet Sci 2002; 24: 111-116.
72. Pons-Guiraud A, Vigan M,. Allergies aux cosmétiques. Textbook, Edition Exp Sc Fr 2003; 37-40.
73. ® Oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inflammatory mediators. Planta Med 2011; 77: 900-906.